{"id":8719,"date":"2026-02-11T00:08:06","date_gmt":"2026-02-11T00:08:06","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/8719\/"},"modified":"2026-02-11T00:08:06","modified_gmt":"2026-02-11T00:08:06","slug":"ozempic-maker-sues-hims-hers","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/8719\/","title":{"rendered":"Ozempic maker sues Hims &#038; Hers"},"content":{"rendered":"<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p class=\"p1\">(CNN)\u2013 Drug maker Novo Nordisk has filed a lawsuit against telehealth provider Hims and Hers over alleged copycat versions of its weight-loss and obesity medications.<\/p>\n<p class=\"p1\">The lawsuit, filed Tuesday, Feb. 10, 2026, accuses Hims and Hers of making compounded knock off versions of the popular drugs Ozempic and Wegovy.<\/p>\n<p class=\"p1\">Novo Nordisk estimates one and a half million people in the U.S. are using compound versions of its drugs.<\/p>\n<p class=\"p1\">When the drugs were in short supply the FDA allowed compounding pharmacies to make similar medications to fill gaps for patients.<\/p>\n<p class=\"p1\">But Ozempic and Wegovy were removed from the shortage list last year.<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 \u00a0 (CNN)\u2013 Drug maker Novo Nordisk has filed a lawsuit against telehealth provider Hims and Hers over&hellip;\n","protected":false},"author":2,"featured_media":8720,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[7150,7151,272],"class_list":{"0":"post-8719","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-glp-1-weight-loss-drugs","9":"tag-hims-and-hers","10":"tag-novo-nordisk"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/8719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=8719"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/8719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/8720"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=8719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=8719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=8719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}